PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, published by TAYLOR & FRANCIS LTD, is a premier academic journal dedicated to advancing our understanding of receptor biology and signal transduction mechanisms. With an ISSN of 1079-9893 and an E-ISSN of 1532-4281, this journal has maintained a reputable standing since its inception in 1980, continually addressing pivotal topics in biochemistry, cell biology, and molecular biology. As evidenced by its 2023 Scopus rankings, which place it in the 64th percentile for Biochemistry and Genetics and Molecular Biology, JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION remains a vital source for cutting-edge research, providing insights that are essential for both academic and practical applications. Although the journal currently offers limited open access options, it stands out in the Q2 and Q3 quartiles of its respective categories, making it an invaluable resource for researchers, professionals, and students aiming to stay abreast of the latest findings and methodologies in receptor and signaling research. The journal's commitment to disseminating high-quality research underscores its significance within the scientific community, fostering innovation and collaboration across disciplines.

Computational and Structural Biotechnology Journal is a premier open-access journal published by Elsevier, focusing on the intersection of computer science and molecular biology. Since its inception in 2012, the journal has established itself as a leading platform for innovative research, featuring groundbreaking studies in biochemistry, biophysics, biotechnology, and genetics. With a remarkable Q1 ranking in multiple categories, including Biochemistry and Genetics, it stands out for its high impact, evidenced by its strong Scopus ranking percentile scores. As a vital resource for researchers, professionals, and students, the journal aims to foster the dissemination of essential findings that leverage computational techniques to explore complex biological systems. In a rapidly evolving scientific landscape, Computational and Structural Biotechnology Journal serves as an indispensable resource for those looking to contribute and stay abreast of major advancements in the field.

BIOSCIENCE REPORTS, published by Portland Press Ltd, is a prestigious journal dedicated to advancing the fields of biochemistry, biophysics, cell biology, and molecular biology. Founded in 1981, the journal has established itself as a vital resource for researchers and professionals, boasting a significant impact factor and high rankings within its categories, including Q2 in Biochemistry and Q1 in Biophysics as of 2023. The journal’s commitment to high-quality, peer-reviewed research ensures that it remains an influential platform for the dissemination of cutting-edge scientific findings. While it operates under a traditional subscription model, it offers various access options to accommodate the needs of the scientific community. With ongoing publication through 2024, BIOSCIENCE REPORTS continues to play a crucial role in shaping discussions in the life sciences and fostering innovative research in biology.

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Molecular Biology Research Communications is a distinguished academic journal published by Shiraz University, focusing on the critical and rapidly evolving fields of biochemistry and molecular biology. With an ISSN of 2322-181X and an E-ISSN of 2345-2005, this journal serves as an essential platform for researchers, professionals, and students to disseminate significant findings that contribute to the advancement of knowledge in these disciplines. The journal, operating from Shiraz, Iran, is notable for its contributions from both local and international scholars, offering invaluable insights and fostering scientific collaboration. Although currently indexed in the Q4 quartile across its categories, the journal aims to enhance its impact and visibility in the field as it converges years of research from 2017 to 2024. While the open access option is not available, the journal's commitment to high-quality peer-reviewed research provides a respected avenue for publication.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.